BIOMAT Database Logo BIOMAT Database Logo

bcr breakpoint location in Spanish patients with chronic myelogenous leukemia. 1992

A Valiente, and J Benitez, and E Prieto

UI MeSH Term Description Entries
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002892 Chromosomes, Human, Pair 22 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 22
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013030 Spain Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid. Balearic Islands,Canary Islands
D015321 Gene Rearrangement The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development. DNA Rearrangement,DNA Rearrangements,Gene Rearrangements,Rearrangement, DNA,Rearrangement, Gene,Rearrangements, DNA,Rearrangements, Gene
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D051562 Proto-Oncogene Proteins c-bcr A serine-threonine kinase that contains a C2 DOMAIN and PLECKSTRIN HOMOLOGY DOMAIN. It also has activity as a GTPASE-ACTIVATING PROTEIN for RAC1 PROTEIN and CDC42 PROTEIN. It functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION and is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients. bcr Proto-Oncogene Proteins,c-bcr Proteins,Breakpoint Cluster Region Protein,Proto-Oncogene Protein bcr,Proto-Oncogene Protein c-bcr,c-bcr Proto-Oncogene Proteins,Proto Oncogene Protein bcr,Proto Oncogene Protein c bcr,Proto Oncogene Proteins c bcr,Proto-Oncogene Proteins, bcr,Proto-Oncogene Proteins, c-bcr,bcr Proto Oncogene Proteins,c bcr Proteins,c bcr Proto Oncogene Proteins,c-bcr, Proto-Oncogene Protein,c-bcr, Proto-Oncogene Proteins

Related Publications

A Valiente, and J Benitez, and E Prieto
Philadelphia-positive chronic myelogenous leukemia with breakpoint 5' of the breakpoint cluster region but within the bcr gene.
December 1987, Blut,
A Valiente, and J Benitez, and E Prieto
bcr-abl RNA in patients with chronic myelogenous leukemia.
March 1987, Blood,
A Valiente, and J Benitez, and E Prieto
Distribution of breakpoint within the breakpoint cluster region (bcr) in chronic myelogenous leukemia with a complex Philadelphia chromosome translocation.
November 1989, American journal of hematology,
A Valiente, and J Benitez, and E Prieto
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
March 2000, Blood,
A Valiente, and J Benitez, and E Prieto
Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis.
November 1988, Cancer genetics and cytogenetics,
A Valiente, and J Benitez, and E Prieto
New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
May 2017, Asian Pacific journal of cancer prevention : APJCP,
A Valiente, and J Benitez, and E Prieto
Chronic myelogenous leukemia, BCR-ABL1+.
August 2009, American journal of clinical pathology,
A Valiente, and J Benitez, and E Prieto
[A relationship between the breakpoint of the bcr gene and some hematologic parameters in patients with chronic myelogenous leukemia].
January 1995, Acta haematologica Polonica,
A Valiente, and J Benitez, and E Prieto
Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia.
June 1995, Leukemia,
A Valiente, and J Benitez, and E Prieto
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
October 1994, Leukemia,
Copied contents to your clipboard!